New allergy drug shows promise for kids in Long-Term trial
NCT ID NCT01900054
First seen Jan 10, 2026 · Last updated May 15, 2026 · Updated 16 times
Summary
This study looked at the long-term safety and effectiveness of TAU-284 (Bepotastine besilate) in children aged 7 to 15 with perennial allergic rhinitis (year-round allergies). Over 12 weeks, researchers tracked side effects and changes in nasal symptoms like sneezing, runny nose, and congestion. The goal was to see if the drug can safely ease allergy symptoms over an extended period.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PERENNIAL ALLERGIC RHINITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Reserch site
Kanagawa, Japan
Conditions
Explore the condition pages connected to this study.